Erlotinib in non-small-cell lung cancer

被引：13

作者：

Gridelli, Cesare ^{[1
]}

Rossi, Antonio ^{[1
]}

Malone, Paolo ^{[1
]}

Colantuoni, Giuseppe ^{[1
]}

Del Gaizo, Filomena ^{[1
]}

Ferrara, Carmine ^{[1
]}

Nicolella, Dario ^{[1
]}

Guerriero, Ciro ^{[1
]}

机构：

[1] SG Moscati Hosp, Div Med Oncol, I-83100 Avellino, Italy

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2007年 / 8卷 / 15期

关键词：

EGFR; erlotinib; NSCLC; small molecule;

D O I：

10.1517/14656566.8.15.2579

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Epidermal growth factor receptor (EGFR) plays an essential role in normal cell growth and differentiation, and is involved in tumour proliferation and survival. EGFR overexpression is a common feature in solid malignancies, including non-small-cell lung cancer (NSCLC), and is associated with poor clinical prognosis. Erlotinib is a small-molecule inhibitor of EGFR tyrosine kinase, showing a significant improvement in median survival, quality of life and related symptoms in an unselected population of advanced NSCLC patients in the second- or third-line setting. Erlotinib is well tolerated (with common toxicities including rash and diarrhoea) when administered at a standard oral daily dose of 150 mg. Further investigations are ongoing to contribute to our understanding of the role of erlotinilb in NSCLC treatment.

引用

页码：2579 / 2592

页数：14

共 50 条

[31] Erlotinib for relapsed or refractory Non-Small-Cell Lung Cancer after failure of gefitinib
Nishihira, Ryuichi
Ogura, Takashi
Tajiri, Michihiko
Kato, Terufumi
Sekine, Akimasa
Shinohara, Takeshi
Baba, Tomohisa
Takahashi, Hiroshi
[J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S703 - S703
[32] EFFECTIVENESS OF ERLOTINIB IN ADVANCED NON-SMALL-CELL LUNG CANCER AFTER FAILURE OF GEFITINIB
Saito, Haruhiro
Murakami, Shuji
Honda, Takeshi
Kondo, Tetsuro
Oshita, Fumihiro
Noda, Kazumasa
Yamada, Kouzo
[J]. ANNALS OF ONCOLOGY, 2010, 21 : 26 - 26
[33] Erlotinib in a patient with acute myelogenous leukemia and concomitant non-small-cell lung cancer
Pitini, Vincenzo
Arrigo, Carmela
Altavilla, Giuseppe
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (21) : 3645 - 3646
[34] Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer
Pérez-Soler, R
Chachoua, A
Hammond, LA
Rowinsky, EK
Huberman, M
Karp, D
Rigas, J
Clark, GM
Santabàrbara, P
Bonomi, P
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) : 3238 - 3247
[35] Neoadjuvant (induction) erlotinib response in stage IIIA non-small-cell lung cancer
Kappers, Ingrid
Klomp, Houke M.
Burgers, Jacobus A.
Van Zandwijk, Nico
Haas, Rick L. M.
van Pel, Renee
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (25) : 4205 - 4207
[36] A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non-Small-Cell Lung Cancer
Goldberg, Sarah B.
Supko, Jeffrey G.
Neal, Joel W.
Muzikansky, Alona
Digumarthy, Subba
Fidias, Panos
Temel, Jennifer S.
Heist, Rebecca S.
Shaw, Alice T.
McCarthy, Patricia O.
Lynch, Thomas J.
Sharma, Sreenath
Settleman, Jeffrey E.
Sequist, Lecia V.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (10) : 1602 - 1608
[37] Designed DNA nanostructure grafted with erlotinib for non-small-cell lung cancer therapy
Wang, Yuqi
Cheng, Jin
Zhao, Di
Liu, Yan
Luo, Tao
Zhong, Yi-Fang
Mo, Fangli
Kong, Xiang-Yang
Song, Jie
[J]. NANOSCALE, 2020, 12 (47) : 23953 - 23958
[38] Role of erlotinib in the targeted treatment of non-small-cell lung cancer in Chinese patients
Li, Wei
Zhou, Fei
Zhou, Caicun
[J]. ONCOTARGETS AND THERAPY, 2014, 7 : 253 - 261
[39] The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer
Neal, Joel W.
[J]. FUTURE ONCOLOGY, 2010, 6 (12) : 1827 - 1832
[40] Erlotinib Versus Gefitinib for Control of Leptomeningeal Carcinomatosis in Non-Small-Cell Lung Cancer
Lee, Eunyoung
Keam, Bhumsuk
Kim, Dong-Wan
Kim, Tae Min
Lee, Se-Hoon
Chung, Doo Hyun
Heo, Dae Seog
[J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (08) : 1069 - 1074

← 1 2 3 4 5 →